Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2010

01-09-2010 | Original Paper

Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer

Authors: Birgitta Schlüter, Roswitha Gerhards, Dirk Strumberg, Rudolf Voigtmann

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2010

Login to get access

Abstract

Purpose

Her2/neu protein overexpression and gene amplification is found in 20–30% of breast cancer patients and correlates with poor clinical outcome. Patients who profit from anti-Her2/neu- therapy are routinely selected by examination of tumour specimens using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) separately. Many studies found a good correlation between both methods for score 1+ samples and for score 3+ samples, but not for score 2+ samples. In this study, we examined pleural and ascitic effusions with a combined approach using IHC and FISH on the same cells, under the following aspects: (1) frequency of Her2/neu protein expression and gene amplification in effusions; (2) correlation between score of protein expression and gene amplification; (3) impact of chromosome 17 polyploidy on Her2/neu protein expression.

Methods

We examined 31 effusions from patients with breast cancer and 4 effusions from patients with ovarian cancer. Cytospins were analysed by IHC using two anti-Her2/neu antibodies and subsequently analysed by FISH with Her2/neu/CEP17 probes. Amplification was defined as: (1) Her2/neu gene copy number of more than 4 and (2) Her2/neu/CEP17 ratio of 2.0 or greater.

Results

A system combining IHC and FISH was developed and 35 effusion specimens were examined. As much as 25 of them were scored as positive. All of them contained cells with heterogeneous scores. A total of 18 of the samples contained cells with scores that ranged from 0 to 3+. In the other samples scores ranged from 0 to 1+ or 0 to 2+. Cells were analysed for Her2/neu gene amplification and chromosome 17 ploidy with regard to their scores. As much as 15 of all samples had mean Her2/neu copy numbers of >4, but only 12% (n = 3) of the positive samples were amplified according to Her2/neu/CEP17 ratio. Only 22, 9% (n = 8) were polyploid (mean CEP17 > 4); but 65, 7% (n = 23) of all specimens contained single polyploid cells. In some cases up to 100% of the score 3+ cells showed chromosome 17 polyploidy. Here protein overexpression might be caused by polyploidy rather than by gene amplification. In some samples, we found single cells with gene amplification but without protein expression and cells without amplification but with protein overexpression.

Conclusion

The combination of IHC and FISH allows a differentiated analysis of single cells, which is especially important for effusions that are composed of heterogeneous cells. Therefore, cells with high gene amplification and/or protein overexpression can be detected and analysed even if their amount in the sample is small. Chromosome 17 polyploidy is important in some cases but this should be further examined on a larger series.
Literature
go back to reference Acs G, Wang L, Raghunath PN, Salscheider MA, Zhang PJ (2003) Role of different immunostaining patterns in Herceptest interpretation and criteria for gene amplification as determined by fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 11(3):222–229PubMed Acs G, Wang L, Raghunath PN, Salscheider MA, Zhang PJ (2003) Role of different immunostaining patterns in Herceptest interpretation and criteria for gene amplification as determined by fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 11(3):222–229PubMed
go back to reference Ainsworth R, Bartlett JM, going JJ, Mallon EA, Forsyth A, Richmond J, Angerson W, Watters A, Dunne B (2005) IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than Herceptest in breast carcinoma. J Clin Pathol 58(10):1086–1090CrossRefPubMed Ainsworth R, Bartlett JM, going JJ, Mallon EA, Forsyth A, Richmond J, Angerson W, Watters A, Dunne B (2005) IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than Herceptest in breast carcinoma. J Clin Pathol 58(10):1086–1090CrossRefPubMed
go back to reference Bermont L, Algros MP, Baron MH, Adessi GL (2000) Relevance of p185 Her-2/neu oncoprotein quantification in human primary breast carcinoma. Breast Cancer Res Treat 63:163–169CrossRefPubMed Bermont L, Algros MP, Baron MH, Adessi GL (2000) Relevance of p185 Her-2/neu oncoprotein quantification in human primary breast carcinoma. Breast Cancer Res Treat 63:163–169CrossRefPubMed
go back to reference Bilous M, Ades C, Armes J et al (2003) Predicting the HER2 status of breast cancer from basic histopathology data, an analysis of 1500 breast cancers as part of the HER 2000 international study. Breast 12:92–98CrossRefPubMed Bilous M, Ades C, Armes J et al (2003) Predicting the HER2 status of breast cancer from basic histopathology data, an analysis of 1500 breast cancers as part of the HER 2000 international study. Breast 12:92–98CrossRefPubMed
go back to reference Bofin AM et al (2003) TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14:314–319CrossRefPubMed Bofin AM et al (2003) TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14:314–319CrossRefPubMed
go back to reference Brison O (1993) Gene amplification and tumour progression. Biochim Biophys Acta 1155:25–41PubMed Brison O (1993) Gene amplification and tumour progression. Biochim Biophys Acta 1155:25–41PubMed
go back to reference Ceccarelli C, Santini D, Gamberoni M (1999) Immunohistochemical expression of internal and external ErbB2 domains in invasive breast cancer. Breast Cancer Res Treat 58:107–114CrossRefPubMed Ceccarelli C, Santini D, Gamberoni M (1999) Immunohistochemical expression of internal and external ErbB2 domains in invasive breast cancer. Breast Cancer Res Treat 58:107–114CrossRefPubMed
go back to reference Chang CH, Chiu JH, Tseng LM, Chang CH, Chien TM, Wu CW, Lui WY (2006) Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur J Clin Invest 36(8):588–596CrossRefPubMed Chang CH, Chiu JH, Tseng LM, Chang CH, Chien TM, Wu CW, Lui WY (2006) Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur J Clin Invest 36(8):588–596CrossRefPubMed
go back to reference Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks D (2005) The influence of polysomy 17 on Her2 gene and protein expression in adenocarcinoma of the breast. Am J Surg Pathol 29(9):1221–1227CrossRefPubMed Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks D (2005) The influence of polysomy 17 on Her2 gene and protein expression in adenocarcinoma of the breast. Am J Surg Pathol 29(9):1221–1227CrossRefPubMed
go back to reference Ervens AM, Otte M, Egen C, Pantel K (2001) Her-2/neu FISH on cytokeratin-positive cells in bone marrow from breast cancer patients: establishment of the method (3rd International Symposium on minimal residual cancer, 16–18-Feb 2001, Hamburg, Germany). Eur J Clin Investig 36(8):588–596 Ervens AM, Otte M, Egen C, Pantel K (2001) Her-2/neu FISH on cytokeratin-positive cells in bone marrow from breast cancer patients: establishment of the method (3rd International Symposium on minimal residual cancer, 16–18-Feb 2001, Hamburg, Germany). Eur J Clin Investig 36(8):588–596
go back to reference Fetsch PA, Abati A (2007) The effect of antibody clone and pre-treatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: a query and a review of the literature. Diagn Cytopathol 35(6):319–328CrossRefPubMed Fetsch PA, Abati A (2007) The effect of antibody clone and pre-treatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: a query and a review of the literature. Diagn Cytopathol 35(6):319–328CrossRefPubMed
go back to reference Glazyrin A, Shen X, Blanc V, Eliason JF (2007) Direct detection of herceptin/trastuzumab binding on breast tissue sections. J Histochem Cytochem 55(1):25–33CrossRefPubMed Glazyrin A, Shen X, Blanc V, Eliason JF (2007) Direct detection of herceptin/trastuzumab binding on breast tissue sections. J Histochem Cytochem 55(1):25–33CrossRefPubMed
go back to reference Gusterson BA, Machin LG, Gullick WJ et al (1988) Immunohistochemical distribution of c-erb-B2 in infiltrating and in situ breast cancer. Int J Cancer 42:842–845PubMed Gusterson BA, Machin LG, Gullick WJ et al (1988) Immunohistochemical distribution of c-erb-B2 in infiltrating and in situ breast cancer. Int J Cancer 42:842–845PubMed
go back to reference Hammock L, Lewis M (2006) Strong Her-2neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 34(10):1043–1047CrossRef Hammock L, Lewis M (2006) Strong Her-2neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 34(10):1043–1047CrossRef
go back to reference Harris LN, Yang L, Liotecheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS (2001) Induction of topoisomerase II activity after erbB2 activation is associated with a different response to breast cancer chemotherapy. Clin Cancer Res 7:1497–1504PubMed Harris LN, Yang L, Liotecheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS (2001) Induction of topoisomerase II activity after erbB2 activation is associated with a different response to breast cancer chemotherapy. Clin Cancer Res 7:1497–1504PubMed
go back to reference Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J (2008) Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 62(1):89–94CrossRef Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J (2008) Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 62(1):89–94CrossRef
go back to reference Hung TL, Chen FF, Liu JM (2003) Clinical evaluation of Her2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as tumor marker in pleural effusion diagnosis. Clin Cancer Res 9:2605–2612PubMed Hung TL, Chen FF, Liu JM (2003) Clinical evaluation of Her2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as tumor marker in pleural effusion diagnosis. Clin Cancer Res 9:2605–2612PubMed
go back to reference Isola J, Tanner M (2004) Chromogenic in situ hybridization in tumour pathology. Methods Mol Med 97:133–144PubMed Isola J, Tanner M (2004) Chromogenic in situ hybridization in tumour pathology. Methods Mol Med 97:133–144PubMed
go back to reference Khosrotehrani K, Stroh H, Bianchi DW (2003) Combined FISH and immunolabeling on paraffin-embedded tissue sections for the study of microchimirism. Biotechniques 34:242–244PubMed Khosrotehrani K, Stroh H, Bianchi DW (2003) Combined FISH and immunolabeling on paraffin-embedded tissue sections for the study of microchimirism. Biotechniques 34:242–244PubMed
go back to reference Kibbelaar RE, van Kamp H, Dreef EJ, de Groot-Swings JC, Kluin-Nelemans JC, Beverstock GC, Fibbe WE, Kluin PhM (1992) Combined immunophenotyping and DNA in Situ hybridization to study lineage involvement in patients with myelodysplatic syndromes. Blood 79:1823–1828PubMed Kibbelaar RE, van Kamp H, Dreef EJ, de Groot-Swings JC, Kluin-Nelemans JC, Beverstock GC, Fibbe WE, Kluin PhM (1992) Combined immunophenotyping and DNA in Situ hybridization to study lineage involvement in patients with myelodysplatic syndromes. Blood 79:1823–1828PubMed
go back to reference Lal P, Salazar PA, Ladanyi M, Chen B (2003) Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinoma without HER-2/neu gene amplification. J Mol Diagn 5:153–159 Lal P, Salazar PA, Ladanyi M, Chen B (2003) Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinoma without HER-2/neu gene amplification. J Mol Diagn 5:153–159
go back to reference Lamy PJ, Nanni Fina F, Bibeau F, Romain S, Dussert C, Penault Llorca F, Grenier J, Quafik LH, Martin PM (2006) Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 21(1):20–29PubMed Lamy PJ, Nanni Fina F, Bibeau F, Romain S, Dussert C, Penault Llorca F, Grenier J, Quafik LH, Martin PM (2006) Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 21(1):20–29PubMed
go back to reference Li-Ning TE (2005) Role of chromogenic in situ hybridization in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol 13(4):343–351CrossRef Li-Ning TE (2005) Role of chromogenic in situ hybridization in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH. Int J Surg Pathol 13(4):343–351CrossRef
go back to reference Lottner Ch, Schwarz St, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G (2005) Simultaneous detection of Her2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 205(5):577–584CrossRefPubMed Lottner Ch, Schwarz St, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G (2005) Simultaneous detection of Her2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 205(5):577–584CrossRefPubMed
go back to reference Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-caldon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart M, Larismont D (2005) Polysomy 17 HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11(12):4393–4399CrossRefPubMed Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-caldon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart M, Larismont D (2005) Polysomy 17 HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11(12):4393–4399CrossRefPubMed
go back to reference Martin-Subero JI, Chudoba I, Harder L, St Gesk, Grote W, Novo FJ, Calasanz MJ, Siebert R (2002) Multicolour-fiction expanding the possibilities of combined morphologic, immunophenotypic and genetic single cell analyses. Am J Pathol 161:413–420PubMed Martin-Subero JI, Chudoba I, Harder L, St Gesk, Grote W, Novo FJ, Calasanz MJ, Siebert R (2002) Multicolour-fiction expanding the possibilities of combined morphologic, immunophenotypic and genetic single cell analyses. Am J Pathol 161:413–420PubMed
go back to reference Meeker AK et al (2002) Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridisation and immunostaining. Am J Pathol 160:1259–1268PubMed Meeker AK et al (2002) Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridisation and immunostaining. Am J Pathol 160:1259–1268PubMed
go back to reference Ni R, Mulligan AM, Have C, Omalley FP (2007) PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for assessment of ErbB2 (Her2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol 15(3):316–324CrossRefPubMed Ni R, Mulligan AM, Have C, Omalley FP (2007) PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for assessment of ErbB2 (Her2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol 15(3):316–324CrossRefPubMed
go back to reference Nowell PC, Rowley JD, Knudson AG (1998) Cancer genetics, cytogenetics—defining the enemy within. Nat Med 4:1107–1111CrossRefPubMed Nowell PC, Rowley JD, Knudson AG (1998) Cancer genetics, cytogenetics—defining the enemy within. Nat Med 4:1107–1111CrossRefPubMed
go back to reference Pandis N, Jin Y, Gorunova L, Pterson C, Bardi G, Idvall I, Johansson B, Ingvar C, Mandahl N, Mitelman F (1995) Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotype subgroups. Genes Chrom Cancer 12:173–185CrossRefPubMed Pandis N, Jin Y, Gorunova L, Pterson C, Bardi G, Idvall I, Johansson B, Ingvar C, Mandahl N, Mitelman F (1995) Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotype subgroups. Genes Chrom Cancer 12:173–185CrossRefPubMed
go back to reference Pauletti G, Dandekar S, Rong HM et al (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence In situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664PubMed Pauletti G, Dandekar S, Rong HM et al (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence In situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664PubMed
go back to reference Pavelic ZP, Pavelic L, Lower EE (1992) C-myc, c-erbB2 and Ki-67 expression in normal breast tissue and in invasive and non-invasive breast carcinoma. Cancer Res 52:2597–2606PubMed Pavelic ZP, Pavelic L, Lower EE (1992) C-myc, c-erbB2 and Ki-67 expression in normal breast tissue and in invasive and non-invasive breast carcinoma. Cancer Res 52:2597–2606PubMed
go back to reference Perez EA (1999) Her-2 as a prognostic, predictive and therapeutic target in breast cancer. Cancer Control 6:233–240PubMed Perez EA (1999) Her-2 as a prognostic, predictive and therapeutic target in breast cancer. Cancer Control 6:233–240PubMed
go back to reference Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE (2002) Her2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clinic Proc 77:148–154CrossRef Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE (2002) Her2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clinic Proc 77:148–154CrossRef
go back to reference Popescu NC, King CR, Kraus MH (1989) Localization of the human erb-B2 gene on normal and rearranged chromosome 17 to bands q12–21.32. Genomics 4:362–366CrossRefPubMed Popescu NC, King CR, Kraus MH (1989) Localization of the human erb-B2 gene on normal and rearranged chromosome 17 to bands q12–21.32. Genomics 4:362–366CrossRefPubMed
go back to reference Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markovicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R et al (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960–4970PubMed Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markovicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R et al (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960–4970PubMed
go back to reference Ridolfi RL, Jamehdor MR, Arber JM (2000) Her2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13(8):866–873CrossRefPubMed Ridolfi RL, Jamehdor MR, Arber JM (2000) Her2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13(8):866–873CrossRefPubMed
go back to reference Ross JS, Fletcher JA, Kenneth JB et al (2004) Targeted therapy in breast cancer: the HER-2 neu gene and protein. Mol Cell Proteomics 3:379–398CrossRefPubMed Ross JS, Fletcher JA, Kenneth JB et al (2004) Targeted therapy in breast cancer: the HER-2 neu gene and protein. Mol Cell Proteomics 3:379–398CrossRefPubMed
go back to reference Sauer T, Beraki K, Jebsen PW, Ormerod E, Naess O (1998) Numerical aberrations of chromosome 17 in interphase cell nuclei of breast carcinoma cells: lack of correlation with abnormal expression of P53, neu and nm23 protein. APMIS 106:921–927CrossRefPubMed Sauer T, Beraki K, Jebsen PW, Ormerod E, Naess O (1998) Numerical aberrations of chromosome 17 in interphase cell nuclei of breast carcinoma cells: lack of correlation with abnormal expression of P53, neu and nm23 protein. APMIS 106:921–927CrossRefPubMed
go back to reference Sauer T, Wiedswang G, Boudjiema G, Christensen H, Karesen R (2003) Assesment of HER2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be method of choice. APMIS 111:444–450CrossRefPubMed Sauer T, Wiedswang G, Boudjiema G, Christensen H, Karesen R (2003) Assesment of HER2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be method of choice. APMIS 111:444–450CrossRefPubMed
go back to reference Schlueter B, Gerhards R, Voigtmann R (2002) Examination of tumour cells in exudate samples from patients with breast cancer and ovarian cancer. Comparison of Her2/neu status and protein expression by simultaneously performed IF and FISH. Abstract. Deutscher Krebskongress, Berlin Schlueter B, Gerhards R, Voigtmann R (2002) Examination of tumour cells in exudate samples from patients with breast cancer and ovarian cancer. Comparison of Her2/neu status and protein expression by simultaneously performed IF and FISH. Abstract. Deutscher Krebskongress, Berlin
go back to reference Slamon DJ, Clark GM, WongSG Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the ERBB2 oncogene. Science 235:177–181CrossRefPubMed Slamon DJ, Clark GM, WongSG Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the ERBB2 oncogene. Science 235:177–181CrossRefPubMed
go back to reference Slamon DJ, Godolphin W, La Jones B, Holt JA, Wang SG, Keith DE (1989) Studies of the ERBB proto-oncogene in human breast and ovarian cancer. Science 244:707–712CrossRefPubMed Slamon DJ, Godolphin W, La Jones B, Holt JA, Wang SG, Keith DE (1989) Studies of the ERBB proto-oncogene in human breast and ovarian cancer. Science 244:707–712CrossRefPubMed
go back to reference Slamon DJ, Leyland-Jones B, Shaks S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783–792CrossRefPubMed Slamon DJ, Leyland-Jones B, Shaks S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783–792CrossRefPubMed
go back to reference St Mc Cormick, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J (2002) Her2 Assessment by immunohistochemical analysis and fluorescence in situ hybridization. Am J Clin Pathol 117:935–943CrossRef St Mc Cormick, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J (2002) Her2 Assessment by immunohistochemical analysis and fluorescence in situ hybridization. Am J Clin Pathol 117:935–943CrossRef
go back to reference Streit A, Stern CD (2001) Combined whole-mount in- situ-hybridisation and immunostaining in avian embryos. Methods 23:339–344CrossRefPubMed Streit A, Stern CD (2001) Combined whole-mount in- situ-hybridisation and immunostaining in avian embryos. Methods 23:339–344CrossRefPubMed
go back to reference Tsuda H (2006) Her-2 (c-erbB-2) test update: present status and problems. Breast Cancer 13:236–248CrossRefPubMed Tsuda H (2006) Her-2 (c-erbB-2) test update: present status and problems. Breast Cancer 13:236–248CrossRefPubMed
go back to reference Tsukamoto F, Miyoshi Y, Egawa Ch, Kasugai T, Takami S, Inazawa J, Noguchi S (2001) Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 93:165–170CrossRefPubMed Tsukamoto F, Miyoshi Y, Egawa Ch, Kasugai T, Takami S, Inazawa J, Noguchi S (2001) Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 93:165–170CrossRefPubMed
go back to reference Van de Vijer M, Petersen JL, Moois WJ et al (1988) Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239–1245CrossRef Van de Vijer M, Petersen JL, Moois WJ et al (1988) Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239–1245CrossRef
go back to reference Varshney D, Zhou YY, Geller SA, Alsabeth R (2004) Determination of Her2 status and chromosome 17 polysomy in breast carinomas comparing hercepttest and PathVysion FISH assay. Am J Clin Pathol 121:70–77CrossRefPubMed Varshney D, Zhou YY, Geller SA, Alsabeth R (2004) Determination of Her2 status and chromosome 17 polysomy in breast carinomas comparing hercepttest and PathVysion FISH assay. Am J Clin Pathol 121:70–77CrossRefPubMed
go back to reference Vincent-Salomon A, MacGrogan G, Couturier J (2003) Calibration of immunohistochemistry for assessment of Her2 in breast cancer: results of French multi-center GEFPICS study. Histopathology 42:337–347CrossRefPubMed Vincent-Salomon A, MacGrogan G, Couturier J (2003) Calibration of immunohistochemistry for assessment of Her2 in breast cancer: results of French multi-center GEFPICS study. Histopathology 42:337–347CrossRefPubMed
go back to reference Vogel CL, Cobleigh M, Tripathy R, Murphy M, Stewart SJ (2001) Superior outcomes with Herceptin (trastuzumab) (H) fluorescence in situ hybridisation (FISH)-selected patients. Proc Am Soc Clin Oncol 20:22a, abstract 86 Vogel CL, Cobleigh M, Tripathy R, Murphy M, Stewart SJ (2001) Superior outcomes with Herceptin (trastuzumab) (H) fluorescence in situ hybridisation (FISH)-selected patients. Proc Am Soc Clin Oncol 20:22a, abstract 86
go back to reference Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2- overexpressing metastatic breast cancer. J Clin Oncol 20:719–726CrossRefPubMed Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2- overexpressing metastatic breast cancer. J Clin Oncol 20:719–726CrossRefPubMed
go back to reference Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians FH, Hynan L, Ashfaq R (2002) Aneusomy 17 in breast cancer: its role in ERBB2 protein expression and implication for clinical assessment of ERBB2 status. Mod Pathol 15:137–145CrossRefPubMed Wang S, Saboorian MH, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Wians FH, Hynan L, Ashfaq R (2002) Aneusomy 17 in breast cancer: its role in ERBB2 protein expression and implication for clinical assessment of ERBB2 status. Mod Pathol 15:137–145CrossRefPubMed
go back to reference Watters AD, Going JJ, Cooke TG, Bartlett JM (2003) Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77:109–114CrossRefPubMed Watters AD, Going JJ, Cooke TG, Bartlett JM (2003) Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77:109–114CrossRefPubMed
go back to reference Weber-Matthiesen K, Winkelmann M, Müller Hermelink A, Schlegelberger B, Grote W (1992) Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumour cells. J Histochem Cytochem 40:171–175PubMed Weber-Matthiesen K, Winkelmann M, Müller Hermelink A, Schlegelberger B, Grote W (1992) Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumour cells. J Histochem Cytochem 40:171–175PubMed
go back to reference Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Alfred DC (2007) American society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43PubMed Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Alfred DC (2007) American society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43PubMed
go back to reference Yamauchi H, Stearns V, Hayes DF (2001) When is a tumour marker ready for prime time? A case study of c-erbB2 as a predictive factor in breast cancer. J Clin Oncol 19:2334–2356PubMed Yamauchi H, Stearns V, Hayes DF (2001) When is a tumour marker ready for prime time? A case study of c-erbB2 as a predictive factor in breast cancer. J Clin Oncol 19:2334–2356PubMed
Metadata
Title
Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer
Authors
Birgitta Schlüter
Roswitha Gerhards
Dirk Strumberg
Rudolf Voigtmann
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0790-2

Other articles of this Issue 9/2010

Journal of Cancer Research and Clinical Oncology 9/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.